NYSE:AGN - Allergan Stock Price, Forecast & News

Allergan's stock was trading at $185.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AGN shares have decreased by 6.7% and is now trading at $173.00. View which stocks have been mosted impacted by Coronavirus.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 13 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Allergan.

Allergan is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Allergan.

Allergan plc (NYSE:AGN) issued its earnings results on Monday, February, 10th. The company reported $5.22 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $4.57 by $0.65. The business earned $4.35 billion during the quarter, compared to analysts' expectations of $4.09 billion. Allergan had a negative net margin of 32.76% and a positive return on equity of 9.82%. The company's quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $4.29 EPS. View Allergan's earnings history.

Allergan announced a quarterly dividend on Wednesday, March 18th. Shareholders of record on Thursday, April 16th will be given a dividend of $0.74 per share on Monday, June 15th. This represents a $2.96 annualized dividend and a yield of 1.71%. The ex-dividend date is Wednesday, April 15th. View Allergan's dividend history.

Allergan declared that its Board of Directors has approved a stock repurchase plan on Tuesday, January 29th 2019, which authorizes the company to repurchase $2,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire up to 4.1% of its shares through open market purchases. Shares repurchase plans are often an indication that the company's board believes its stock is undervalued.

15 equities research analysts have issued twelve-month price targets for Allergan's stock. Their forecasts range from $144.95 to $203.00. On average, they expect Allergan's stock price to reach $180.08 in the next year. This suggests a possible upside of 4.1% from the stock's current price. View analysts' price targets for Allergan.

Media coverage about AGN stock has trended somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Allergan earned a news impact score of -1.8 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutAllergan.

Allergan saw a decline in short interest during the month of February. As of February 14th, there was short interest totaling 13,700,000 shares, a decline of 11.0% from the January 30th total of 15,400,000 shares. Based on an average daily trading volume, of 2,390,000 shares, the short-interest ratio is presently 5.7 days. Currently, 4.2% of the shares of the company are short sold. View Allergan's Current Options Chain.

Some companies that are related to Allergan include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Zoetis (ZTS), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), United Rentals (URI) and Transocean (RIG).

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

Allergan's stock is owned by many different institutional and retail investors. Top institutional shareholders include State Street Corp (4.39%), Franklin Resources Inc. (2.24%), Longview Partners Guernsey LTD (2.10%), Renaissance Technologies LLC (1.53%), Geode Capital Management LLC (1.45%) and Norges Bank (1.19%). Company insiders that own Allergan stock include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi, Matthew M Walsh and William Meury. View institutional ownership trends for Allergan.

AGN stock was sold by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Assenagon Asset Management S.A., Fred Alger Management LLC, MUFG Securities EMEA plc, State Street Corp, Janus Henderson Group PLC, FMR LLC, and Nuveen Asset Management LLC. View insider buying and selling activity for Allergan.

AGN stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Renaissance Technologies LLC, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp, Segantii Capital Management Ltd, Bank of Montreal Can, Beryl Capital Management LLC, Laurion Capital Management LP, and FIL Ltd. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi, and Matthew M Walsh. View insider buying and selling activity for Allergan.

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AGN stock can currently be purchased for approximately $173.00.

Allergan has a market capitalization of $56.92 billion and generates $16.09 billion in revenue each year. The company earns $-5,271,000,000.00 in net income (profit) each year or $17.64 on an earnings per share basis. Allergan employs 17,400 workers across the globe. View additional information about Allergan.

The official website for Allergan is http://www.allergan.com/.

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]